Bicifadine

Drug Profile

Bicifadine

Alternative Names: CL 220075; DOV 220075

Latest Information Update: 02 Mar 2009

Price : $50

At a glance

  • Originator Wyeth
  • Developer DOV Pharmaceutical; XTL Biopharmaceuticals
  • Class Heterocyclic bicyclo compounds; Non-opioid analgesics; Small molecules
  • Mechanism of Action Adrenergic receptor antagonists; Dopamine uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Diabetic neuropathies; Osteoarthritis; Pain

Most Recent Events

  • 18 Nov 2008 Top-line efficacy data from a phase IIb trial in Diabetic neuropathic pain released by XTL Biopharmaceuticals
  • 09 Oct 2008 XTL Biopharmaceuticals completes a phase IIb trial in Diabetic neuropathies in US, Germany, Israel and India
  • 30 Jun 2008 XTL completes randomisation in its phase IIb trial for diabetic neuropathic pain in the US, Germany, Israel & India
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top